Nabi Biopharmaceuticals (NABI)
Nabi Biopharmaceuticals Profit Margin: -68.99%
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
NABI Profit Margin Rankings
| Overall | 6th percentile | 4104 of 4397 |
| Sector | 28th percentile | 333 of 469 in Healthcare |
| Industry | 54th percentile | 60 of 132 in Biotechnology |
NABI Profit Margin Range, Past 5 Years
| Minimum | -238.3% | Dec 2011 |
| Maximum | 41.63% | Sep 2010 |
| Average | -60.59% |
About Profit Margin
Profit margin represents the percentage of revenue that a company keeps as profit after accounting for fixed and variable costs. It is calculated by dividing net income by revenue. The profit margin is mainly used for internal comparisons, because acceptable profit margins vary between industries. In general, narrow profit margins indicate increased volatility. For companies with significant fixed costs, wide profit margins reduce the risk that a decline in sales will cause a net profit loss.
Displayed as a percentage, profit margin can be thought as the amount of profit that a company keeps per dollar of revenue. For example, if a company has a profit margin of 43%, the company keeps $.43 of each dollar of revenue.
Learn More
You may also be interested in these NABI related companies
NABI News
Listen to $NABI Q1 2012 earnings call - live at 04:30 PM, ondemand after - http://stks.co/3mBZ
about 20 days ago by earningscast
about 20 days ago by earningscast
Nabi Biopharmaceuticals Announces First Quarter 2012 Financial Results Release Date
May 03, 4:35PM GlobeNewswire
May 03, 4:35PM GlobeNewswire
Nabi (NABI) Announces Reverse Merger With Biota Holdings, Current Holders Will Own 26% of New Co.
Apr 23, 7:09AM Street Insider
Apr 23, 7:09AM Street Insider
Nabi Biopharmaceuticals Announces Definitive Merger Agreement With Biota Holdings
Apr 23, 7:08AM Benzinga
Apr 23, 7:08AM Benzinga
Nabi Biopharmaceuticals Announces Definitive Merger Agreement With Biota Holdings Limited
Apr 23, 7:00AM GlobeNewswire
Apr 23, 7:00AM GlobeNewswire
Listen to $NABI Q4 2011 earnings call - live at 04:30 PM, ondemand after - http://stks.co/2rHq
about 77 days ago by earningscast
about 77 days ago by earningscast
Nabi Biopharmaceuticals Announces Fourth Quarter and Full-Year 2011 Financial Results
Mar 14, 4:05PM GlobeNewswire
Mar 14, 4:05PM GlobeNewswire
Nabi Biopharmaceuticals to Announce 2011 Fourth Quarter and Year-End Financial Results on March 14, 2012
Mar 07, 12:29PM GlobeNewswire
Mar 07, 12:29PM GlobeNewswire
@anthony73 I just watch $NABI as an example of buying a stock because it dropped big...Waste of money as it's flatlined.
about 95 days ago by Urbane_Gorilla
about 95 days ago by Urbane_Gorilla
@Urbane_Gorilla $NABI... ouch. Even a tight stop loss in that situation wouldn't help you out.
about 95 days ago by anthony73
about 95 days ago by anthony73
@anthony73 yep $CBRX on my radar as well....Just don't get caught in a $NABI ....I look at $NABI every week as a reminder.
about 96 days ago by Urbane_Gorilla
about 96 days ago by Urbane_Gorilla
@Flynt2012 RE: $URRE .. Lo-o-o-ng term ..sure ...But you only have to look at the chart for $NABI to ask how long..LOL!
about 97 days ago by Urbane_Gorilla
about 97 days ago by Urbane_Gorilla
Nabi Biopharma $NABI Says Second NicVAX(R) Phase III Trial Failed to Meet Primary Endpoint; Reviewing Strategic Alternatives, Hires Piper
about 206 days ago by Street_Insider
about 206 days ago by Street_Insider
Nabi Biopharmaceuticals Announces Results of Second NicVAX(R) Phase III Clinical Trial
Nov 07, 8:30AM GlobeNewswire
Nov 07, 8:30AM GlobeNewswire
Nabi Biopharmaceuticals (NABI) Reports Q3 Loss of $0.07, Sales Fall Short
Nov 02, 5:15PM Street Insider
Nov 02, 5:15PM Street Insider
Nabi Biopharmaceuticals Announces Third Quarter 2011 Financial Results Release Date
Oct 26, 8:00AM GlobeNewswire
Oct 26, 8:00AM GlobeNewswire
$NABI long setup. Trading near resistance line. High (green) volume on thursday. http://chart.ly/coqfndi
about 228 days ago by BioStockAddict
about 228 days ago by BioStockAddict
$NABI http://chart.ly/v4sxmjf could be played either way... look for volume expansion if it breaks to the upside
about 286 days ago by stt2318
about 286 days ago by stt2318
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| NABI | 1.60 | +0.00 | +0.00% | 68.62M |
| N | 46.64 | -0.30 | -0.64% | 3.260B |
| MZZ | 32.80 | +1.23 | +3.90% | |
| MYY | 28.65 | +0.54 | +1.94% | |
| MYRX | 2.45 | -0.07 | -2.78% | 66.48M |
| MYN | 14.42 | +0.01 | +0.07% | |
| MYM | 14.28 | +0.02 | +0.14% | |
| MYL | 21.53 | -0.36 | -1.64% | 9.345B |
| MYJ | 16.13 | -0.14 | -0.86% | |
| MYGN | 24.98 | -0.22 | -0.87% | 2.124B |